ArticleCanadian journal of pain = Revue canadienne de la douleur2026
Prevalence of Risk of Iron Deficiency.
Article in Canadian journal of pain = Revue canadienne de la douleur, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Iron deficiency (ID), a common cause of anemia, disproportionately affects women of reproductive age and is characterized by symptoms such as fatigue, cognitive fog, migraines, restless‑leg syndrome, and musculoskeletal pain. Some of these are also common to chronic pain syndromes. Iron is essential for the synthesis of multiple neurotransmitters, suggesting a mechanistic link between ID and pain perception. Methods: This single‑center cross-sectional study assessed the prevalence of risk factors for iron deficiency among 81 women attending the Michael G. DeGroote Pain Clinic. Participants completed a validated questionnaire adapted from Dr. Toby Richards' Iron Clinic, which evaluated risk factors including heavy menstrual bleeding, prior iron‑deficiency status, and supplementation history. Patients were defined as being at high risk for ID if they endorsed two or more positive symptoms within Question 14 (menstrual‑bleeding characteristics). Results: Overall, 54% of participants were identified as high risk for iron deficiency. 46% reported having restless‑leg syndrome, 47% reported a history of anemia or ID, 41% had taken oral iron supplements, and 15% were receiving iron‑infusion therapy. These results indicate that a substantial proportion of women with chronic pain may also have unrecognized ID. Discussion: Since iron's role in neurotransmitter metabolism provides a plausible biological mechanism for some symptomatology, and there is overlap of the symptoms of ID and chronic pain conditions, routine screening for ID, along with patient education, dietary optimization, oral iron supplementation, and intravenous iron therapy, should be considered as part of integrative pain‑management strategies. Cost-effectiveness analyses support ferritin screening as a feasible approach in this population, highlighting the potential for improved patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.